Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

Inclusion criteria

• 18 years or older
• type 2 diabetes
• A1c 7.1 - 11
• BMI 25 - 45
• stable weight for 3 months before screening
• fasting glucose < 280 at screening
• stable dose of metformin for at least 2 months before screening
• not being treated with or on a stable dose of hormone replacement therapy, oral contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement therapy, anti-depressants, drugs known to affect body weight
• male or female, non-lactating, non-pregnant and willing to use birth control
• lab values that are not clinically significant at screening
• physical exam and ECG that are not clinically significant at screening
• able to read, understand, and sign consent form

Exclusion criteria

• liver disease
• renal disease
• cardiovascular disease
• gastroparesis
• cancer within 5 years of screening
• macular edema
• chronic infections
• drug or alcohol abuse
• fasting triglycerides > or = 600 at screening
• previous exposure to exenatide LAR
• has donated blood within 60 days of screening or is planning to donate during the study
• has had a major surgery or blood transfusion within 2 months before screening
• is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin
• has received an investigational drug within 1 month before screening
• has allergies or hypersensitivity to any component of the study drug
• has previously had an adverse event related to TZD or Januvia
• is an immediate family member of the study sight or directly affiliated
• is employed by Amylin, Lilly or Alkermes